Pfizer (NYSE:PFE) Trading 3.2% Higher Following Analyst Upgrade

Pfizer Inc. (NYSE:PFE)’s stock price shot up 3.2% during mid-day trading on Tuesday after HSBC raised their price target on the stock from $29.00 to $32.00. HSBC currently has a buy rating on the stock. Pfizer traded as high as $27.76 and last traded at $27.4720. 59,452,849 shares traded hands during mid-day trading, an increase of 27% from the average session volume of 46,669,520 shares. The stock had previously closed at $26.61.

A number of other research analysts have also weighed in on PFE. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. BMO Capital Markets reiterated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.14.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 2 data — Pfizer said its atirmociclib combination cut the risk of disease progression or death by ~40% in a randomized mid‑stage breast cancer trial, supporting the drug’s commercial and pipeline value. Read More.
• Positive Sentiment: Analyst upgrade and target lift — HSBC raised its price target from $29 to $32 and put a “buy” rating on PFE, signaling more upside in sell‑side expectations and likely supporting near‑term buying interest. Read More.
• Positive Sentiment: Deal spillover lifts peers/investors — IP Group said NAV rose after Pfizer’s acquisition of Metsera, underscoring Pfizer’s active M&A in obesity and reinforcing investor confidence in dealmaking that can add late‑stage assets. Read More.
• Neutral Sentiment: Ongoing pipeline progress — Pfizer continues to advance multiple trials (new tafamidis formulation, pediatric etrasimod, multivalent pneumococcal vaccine PG4 analysis), which supports longer‑term revenue diversification but is not an immediate revenue driver. Read More.
• Neutral Sentiment: Analyst and retail attention — Zacks and other outlets are highlighting PFE and investors are comparing Pfizer vs. peers like BMY as they weigh oncology pipeline strength; this attention can amplify moves but is not a direct fundamental change. Read More.
• Negative Sentiment: Ongoing revenue risk and loss of exclusivity — analysts and retail commentary warn that Pfizer’s COVID‑era revenue normalisation and looming patent expiries on legacy drugs remain a key risk to sustaining past revenue levels. Investors should weigh clinical wins against these structural revenue headwinds. Read More.

Institutional Trading of Pfizer

Institutional investors have recently modified their holdings of the stock. Norges Bank bought a new position in Pfizer in the 2nd quarter valued at about $2,270,157,000. Morgan Stanley boosted its position in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after purchasing an additional 13,581,757 shares in the last quarter. Vanguard Group Inc. lifted its stake in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

The business has a fifty day moving average price of $26.53 and a 200 day moving average price of $25.54. The company has a market cap of $156.21 billion, a price-to-earnings ratio of 20.20 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.